|
|
|||
| "The important thing is not to stop questioning. Curiosity has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvelous structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day. Never lose a holy curiosity." ---- Albert Einstein We believe that research is needed to improve Diabetes Care and we have a commitment to participation in clinical research projects to advance knowledge of Diabetes. We have participated in research projects, which we feel offer significant benefits to our patients and advance the cause of effective Diabetes care. TAKEDA SYR-322_305 Sponsor: Takeda Global Research & Development Center, Inc. Purpose: To assess the efficacy and safety of alogliptin plus metformin compared to glipizide plus metformin in subjects with type 2 diabetes mellitus whose blood sugar level is inadequately controlled on metformin therapy. The duration of this study will be approximately 2 years. __________________________________________________________________________________ NN2211-1842 Sponsor: Novo Nordisk Purpose: This trial is being conducted in Europe and North America. The aim of this clinical trial is to assess and compare the efficacy of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in people with type 2 diabetes. __________________________________________________________________________________ EFC6016-GETGOAL-L Sponsor: Sanofi aventis Purpose: A double-blind, randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with type 2 diabetes who are insufficiently controlled with basal insulin. __________________________________________________________________________________ Diabetes Prevention Study (ORIGIN Study) Sponsor: Sanofi aventis Purpose: People with IFG, IGT or early diabetes who have evidence of cardiovascular disease have been recruited for this study and are being followed to determine if either insulin glargine-mediated normoglycemia and/or omega- 3 PUFA reduce or prevent incident cardiovascular events. This is a five year study. __________________________________________________________________________________ EFC6017-GETGOAL-P Sponsor: Sanofi aventis Purpose: A double-blind, randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy of AVE0010 in addition to pioglitazone in patients with type 2 diabetes who are not adequately controlled with pioglitazone alone. __________________________________________________________________________________ Merck 0431 128-00 Sponsor: Merck & Co. Purpose: This study is being conducted to evaluate the safety and efficacy of the addition of sitagliptin (MK-0431) in patients with type 2 diabetes mellitus who have inadequate control on combination therapy with metformin and pioglitazone. __________________________________________________________________________________ Apidra_L_04879 (Insulin glulisine) Purpose: To identify patients’ characteristics associated with achieving target metabolic control in real life settings after 3 months treatment with Apidra in type 1 and 2 diabetes mellitus patients previously uncontrolled on basal insulin +/- other anti-diabetic treatment. ___________________________________________________________________________________ LANTU_L_04695 START Sponsor: Sanofi aventis Purpose: To evaluate two approaches of blood glucose monitoring and insulin titration (patient-managed vs. health care professional) in type 2 diabetes mellitus patients while receiving the addition of 1 injection of insulin glulisine (Apidra) at breakfast following optimization of insulin glargine (Lantus). Insulin glargine (Lantus) and insulin glulisine (Apidra) will be provided for the study. Duration of the study is 24 months. | |||